1	Most Hospitalized Patients with Significant Tricuspid Regurgitation Have Advanced
2	Disease Preventing Transcatheter Tricuspid Valve Intervention
3	
4	Short Title: Most Significant TR Patients Not TTVI Candidates
5	
6	Allison O. Dumitriu Carcoana, B.A. ^a , Christopher B. Scoma, M.D. ^b , Sebastian N. Maletz, B.S. ^a ,
7	Jose A. Malavet, B.S. ^a , Daniela R. Crousillat, M.D. ^{a,b} , and Fadi A. Matar, M.D. ^{a,b}
8	
9	The University of South Florida Health Morsani College of Medicine, Tampa, FL, USA ^a and The
10	Heart & Vascular Institute, Tampa General Hospital, Tampa, FL, USA ^b
11	
12	Total word count: 7,020
13 14 15 16 17	Address for correspondence
18	Fadi A. Matar, MD, FACC, FSCAI
19 20 21 22 23 24 25 26	Associate Professor of Medicine, Associate Director of Clinical Services University of South Florida Morsani College of Medicine Chief of Cardiology & Cath Lab Director Tampa General Hospital 509 South Armenia Avenue Tampa, FL 33609
27	Telephone: 813-917-4752
28	E-mail: fmatar@usf.edu
29	
30	

31 ABSTRACT

Background: More than moderate tricuspid regurgitation (TR) is associated with high mortality.
Surgical tricuspid valve repair and replacements are rarely performed due to high operative
mortality risk, mainly attributed to late presentation. Novel transcatheter tricuspid valve
intervention (TTVI) devices are being developed as an alternative to surgery. The population of
patients presenting to tertiary care centers who can benefit from TTVI has not been well defined.
Our objective was to study the characteristics of these patients and to define the sub-population
who may be candidates for TTVI.

Methods: We analyzed 12,677 consecutive 2D echocardiograms completed at our tertiary care 39 center between March 2021 and March 2022 and identified 581 inpatients with more than 40 moderate TR. Clinical and echocardiographic data were collected by individual chart review. 41 The 2021 European Society of Cardiology (ESC) guidelines on the management of valvular 42 disease are currently the only guidelines that include TTVI. We used these guidelines to 43 retrospectively assign the 581 patients to medical therapy, surgery, or TTVI treatment. 44 **Results:** 470 patients (80.9%) were assigned to medical therapy, 57 (9.8%) were assigned to 45 TTVI, and 54 (9.3%) were assigned to tricuspid valve surgery. Of note, 76.2% (443/581) of 46 patients were precluded from any intervention due to advanced disease or anatomic ineligibility, 47 48 and only 4.6% (27/581) presented too early for intervention, being both asymptomatic and without RV dilatation. 49

Conclusion: Only 9.8 percent of patients presenting to a tertiary care center with significant TR
would be hypothetical candidates for TTVI when these technologies are approved in the United
States. Earlier identification and treatment of TR could increase the number of patients who may
benefit from interventions including TTVI.

54 CLINICAL PERSPECTIVE

55 What is New?

56	•	Most patients presenting to a tertiary care center with significant TR are too advanced for
57		any intervention and have high in-hospital and late mortality rates.
58	•	Tertiary care centers planning to offer TTVI should expect that, based on the current ESC
59		guidelines and late presentation of TR, approximately 10% of patients with more than
60		moderate TR will be TTVI candidates.
61		
62	What	are the clinical implications?
	What •	are the clinical implications? There is a need to improve care for patients with TR through earlier detection and referral
62		-
62 63		There is a need to improve care for patients with TR through earlier detection and referral
62 63 64	•	There is a need to improve care for patients with TR through earlier detection and referral for intervention.

68 INTRODUCTION

More than moderate tricuspid regurgitation (TR) is associated with high operative 69 mortality.¹⁻⁸ Due to significant operative risk, surgical TVR is uncommonly performed due in 70 part to late clinical presentation.⁹⁻¹² Several new transcatheter tricuspid valve intervention 71 (TTVI) devices are being developed as a lower-risk alternative to surgery. Many of these devices 72 are in use in Europe and are in the process of being evaluated for approval in the United States.¹³ 73 The prevalence of moderate and severe TR in the United States is estimated at 1,600,000.¹⁴ 74 However, the population of TR patients who can benefit from TTVI is yet to be defined. 75 76 Furthermore, The European Society of Cardiology (ESC) 2021 guidelines for the management of valvular heart disease are the only guidelines that currently include TTVI as a treatment option.¹⁵ 77 As these therapies become available in the United States¹³, it is essential to understand the 78 79 patient populations who may best benefit. In this study, we examined the clinical and echocardiographic variables of patients with significant TR presenting to a tertiary care center 80 81 and defined the sub-population who may be candidates for TTVI, based on the ESC guidelines.

82

83 METHODS

We retrospectively identified 12,677 consecutive patients age ≥18 years who had a transthoracic echocardiogram performed at our center between March 2021 and March 2022. Of these, we collected the clinical and demographic information of 581 patients with more than moderate TR. A consistent group of cardiologists graded TR severity. To further justify our analysis, two cardiologists (C.B.S., D.R.C.) independently re-reviewed 10% of the echocardiograms. The difference of proportions was calculated to validate reliability of categorical parameters prone to some degree of subjectivity. The potentially subjective 91 parameters of importance to our study were the presence of more than moderate TR and the presence of severe right ventricular (RV) dysfunction. For TR severity, the difference of 92 proportions was 0.05 with a standard error of 0.03 and a p-value of 0.0793. For RV dysfunction, 93 the standard error was 0.12 ± 0.07 with a p-value of 0.0791. Thus, we cannot conclude that there 94 was a significant difference between the original and repeated echocardiogram reviews, 95 substantiating consistent grading of these parameters. 96

We used the process described below to place patients into one of three retrospectively

assigned treatment groups: medical therapy, surgery, or TTVI (Figure 1).¹⁵ The retrospectively 98

assigned treatments were not necessarily those applied in actual practice. Our Institutional 99

Review Board (USF IRB Administrative Review; FWA No. 00001669) determined that this 100

protocol met the criteria for exemption from IRB review. One author (F.A.M.) had full access to 101

102 all the data in the study and takes responsibility for its integrity and the data analysis.

103

97

Definitions 104

Modified ESC Algorithm 105

The ESC guidelines recommend that a multidisciplinary Heart Team should determine patients' 106 candidacy for surgery vs. TTVI. In clinical practice, all patients under consideration for TV 107 surgery would be evaluated based on their clinical characteristics. However, the ESC guidelines 108 do not specify the criteria that should be used for surgical candidacy. Our hypothetical Heart 109 110 Team identified patients with age ≥ 80 or prior history of open-heart surgery, valve surgery, cirrhosis, or end-stage renal disease as too high risk for surgery. Patients considered for surgery 111 based on ESC criteria who were too high risk based on Heart Team criteria were assigned to 112 113 TTVI. Patients with primary TR who were too high-risk for surgery and not anatomically viable

114	candidates for TTVI based on endocarditis or congenital TR etiology were assigned to medical
115	therapy. Our modifications to the ESC algorithm are depicted in Figure 2 and Figure 3.
116	

117 Need for Left-Sided Valve Surgery

118 The first step was to determine whether patients needed left-sided valve surgery, criteria 119 not well-defined in the ESC guidelines. We defined qualification for left-sided valve surgery as 120 >moderate mitral or aortic valve regurgitation or stenosis plus meeting Heart Team criteria. The 121 patients who did not qualify were then divided by primary and secondary TR etiologies.

122

123 Primary TR Without Left Sided Valve Dysfunction

Primary TR included endocarditis, carcinoid, lead impingement, and congenital causes. 124 The ESC guidelines recommend first determining whether these patients had symptoms of right 125 heart failure (RHF). NYHA class was not available for over half of our cohort, therefore; we 126 127 defined signs of RHF as lower extremity edema or ascites around the time of the echocardiogram. Asymptomatic patients were then assessed for RV dilatation. RV dilatation was 128 determined in accordance with the 2015 American Society of Echocardiography (ASE) 129 130 recommendations for cardiac chamber quantification, including basal diameter >41mm, mid diameter >35mm, or longitudinal diameter >83mm.¹⁶ Asymptomatic patients without RV 131 dilatation were assigned to medical therapy. Patients with symptoms or RV dilatation were 132 133 evaluated for surgical candidacy. Those who qualified were assigned to tricuspid valve surgery, while those at too high a surgical risk were assigned to TTVI. 134

135

136 Secondary TR Without Left Sided Valve Dysfunction

137	The ESC guidelines recommend that for the patients who do not qualify for left-sided
138	surgery and have secondary TR: severe RV dysfunction, severe LV dysfunction, and severe
139	pulmonary hypertension are exclusion criteria from any intervention, surgical or transcatheter.
140	We assessed the degree of dysfunction based on the echocardiograms using criteria from the
141	2015 ASE recommendations. ¹⁶ Severe RV dysfunction was qualitatively described and
142	confirmed quantitively with a TAPSE <17 mm or an S' <10 cm/s. Severe LV dysfunction was
143	defined as LVEF <30%. Severe pulmonary hypertension was defined as right ventricular systolic
144	pressure >55 mmHg or TR jet velocity >3.6m/s with systolic septal flattening. The patients who
145	met at least one criterion had advanced disease preventing the use of any intervention and were
146	assigned to the medical therapy group.
147	Of the remaining patients, those who were asymptomatic with no RV dilatation were
148	assigned to medical therapy. Those who were symptomatic or asymptomatic with RV dilatation
149	were assigned to either surgery or TTVI based on Heart Team criteria.
	were assigned to entiter surgery of 11 vi based on mourt round enterna.
150	were assigned to entitel surgery of 11 vi cused on front from enterna.
150 151	Early vs. Late Presentation
151	Early vs. Late Presentation
151 152	<i>Early vs. Late Presentation</i> We divided the medical therapy group by early and late presenters, so that TR etiology
151 152 153	<i>Early vs. Late Presentation</i> We divided the medical therapy group by early and late presenters, so that TR etiology and mortality data could be more accurately assessed with respect to disease severity. Patients
151 152 153 154	<i>Early vs. Late Presentation</i> We divided the medical therapy group by early and late presenters, so that TR etiology and mortality data could be more accurately assessed with respect to disease severity. Patients without need for left-sided valve surgery who have secondary TR without severe LV
151 152 153 154 155	<i>Early vs. Late Presentation</i> We divided the medical therapy group by early and late presenters, so that TR etiology and mortality data could be more accurately assessed with respect to disease severity. Patients without need for left-sided valve surgery who have secondary TR without severe LV dysfunction, severe RV dysfunction, severe pulmonary hypertension, symptoms of RHF, and RV

159 On the other hand, patients with severe LV or RV dysfunction or severe pulmonary 160 hypertension were precluded from any intervention and were therefore assigned to medical 161 therapy due to advanced stage disease. In our modified ESC algorithm, we also considered the 162 primary TR patients assigned to medical therapy due to high surgical risk and anatomical 163 unviability for TTVI as advanced.

164

165 **TR Etiology**

We determined the subtype of functional TR based on the process described by Topilsky 166 et al.¹⁷ Left-sided valvular disease was defined as greater than moderate mitral or aortic valve 167 regurgitation or stenosis. LV systolic dysfunction was defined as LVEF <40% and the absence of 168 169 moderate-severe left valvular disease. Severe pulmonary hypertension was defined as pulmonary 170 arterial pressure >55 mmHg or TR jet velocity >3.6m/s with systolic septal flattening and the absence of both moderate-severe left sided valvular disease and LV systolic dysfunction. Isolated 171 TR was defined by the absence of severe pulmonary hypertension, moderate-severe left valvular 172 disease, and LV systolic dysfunction. 173

174

175 Statistics

The standard error of proportions was calculated between the original and repeated assessments of TR severity and RV dysfunction for 10% of the echocardiograms included in this study. This was done to validate the reliability of these parameters because they may be prone to some degree of subjectivity. We reported mean \pm standard deviation or median and first and third quartile (Q1, Q3) values for continuous variables and frequency (percentage) for categorical variables. Variables that did not follow a normal distribution curve were reported as median (Q1,

182	Q3). Cox regression analysis was used for survival analysis, presented as the median survival
183	time with standard deviation and 95% confidence intervals. Kaplan-Meier curves were generated
184	to compare overall survival between the whole cohort compared to survival curves of each
185	treatment group, with medical therapy divided into early and advanced groups. IBM SPSS
186	Statistics for Macintosh, Version 29.0, was used for survival analysis.
187	
188	RESULTS
189	Patient Characteristics
190	Table 1 displays a summary of all clinical data collected for the 581 patients with more
191	than moderate TR. In this cohort, 52.3% (304/581) were women, 56.3% (325/577) were White,
192	and the average age was 65.7 years. Of note, lower extremity edema was present in 67.8%
193	(394/581), ascites in 34.3% (199/581), cirrhosis in 17.7% (103/581), and atrial fibrillation or
194	flutter in 60.9% (354/581). Of the patients who had NYHA class noted in their chart, 78.5%
195	(234/298) were NYHA class III or IV. Table 2 displays the echocardiographic parameters of the
196	581 patients. 92.8% (539/581) had functional TR. The median TAPSE was 15 mm, median
197	RVSP 58 mmHg, and 57.0% (306/537) had severe pulmonary hypertension.
198	
199	Treatment Groups Assigned Using the ESC 2021 Guidelines
200	Figure 3 displays the numbers of patients who were assigned to each treatment group of
201	the modified ESC algorithm.
202	
203	Need for Left-Sided Valve Surgery

205

64 patients had >moderate mitral regurgitation, mitral stenosis, aortic regurgitation, or aortic stenosis. Of these, 25 qualified for surgery and 39 were too high risk.

206

207 Primary TR Without Left Sided Valve Dysfunction

208	40 of the 556 patients who did not qualify for left-sided valve surgery had primary TR.
209	Of these, 23 had symptoms of RHF, and 17 did not. Of the 23 symptomatic patients, 12 were too
210	high risk for surgery. Of these 12, seven had endocarditis $(n = 6)$ or congenital $(n = 1)$ TR
211	etiologies, characterizing anatomic ineligibility for percutaneous treatment via TTVI, and were
212	therefore assigned to medical therapy. The remaining five were appropriate for TTVI with
213	carcinoid $(n = 4)$ or lead impingement $(n = 1)$ TR etiologies.

The 17 asymptomatic patients were assessed for RV dilatation. Eight had RV dilatation, and of these, three were appropriate for surgery. The other five had endocarditis, so they were assigned to medical therapy. The nine remaining patients who were both asymptomatic and without RV dilatation were assigned to medical therapy based on the ESC guidelines.

218

219 Secondary TR Without Left Sided Valve Dysfunction

The remaining 516 patients who did not qualify for left-sided valve surgery had secondary (functional) TR. Of these, 431 had severe LV or RV dysfunction or severe pulmonary hypertension and were assigned to medical therapy. Of the 85 patients without severe dysfunction, 55 patients were symptomatic; 12 were appropriate for surgery, and 43 were assigned to TTVI instead. Regarding the 30 asymptomatic patients, 18 had no RV dilatation and

225	were assigned to medical therapy. The remaining 12 underwent assessment by Heart Team
226	criteria, and three were ultimately appropriate for surgery, while nine were assigned to TTVI.
227	

228 Assigned Treatment Groups

In total, 470 patients (80.9%) were assigned to medical therapy, 57 (9.8%) were assigned to TTVI, and 54 (9.3%) were assigned to tricuspid valve surgery. TV surgery can be further divided into concomitant (n = 25/54, 46.3.0%) and isolated tricuspid valve surgeries (n = 29/54, 53.7%). Of note, 76.2% (443/581) of patients were precluded from any intervention due to advanced ventricular dysfunction, severe pulmonary hypertension, or anatomic ineligibility, and only 4.6% (27/581) presented too early for intervention, being both asymptomatic and without RV dilatation.

Table S1 describes the clinical characteristics of each assigned treatment group, and Table S2 presents their echocardiographic parameters. Table 3 displays the TR etiologies in each treatment group. In Table 3, we divide the medical therapy group by early and late presentation.

240 Concomitant CABG

In clinical practice, TV surgery is also performed with concomitant Coronary Artery Bypass Graft surgery (CABG), but it is not included in the 2021 ESC guidelines. In our cohort, 2.9% (17/581) of patients were possible candidates for CABG based on coronary angiography performed within six months of the index echocardiogram. Of these 17 patients, only three remained surgical candidates after applying the Heart Team criteria. Two of these three were already assigned to TV surgery, and the remaining patient had been assigned to medical therapy

247	due to advanced stage. Thus, the addition of concomitant CABG as a consideration for assigning
248	treatment groups in our cohort would result in approximately equal cohort numbers. One patient
249	in our cohort (whom we assigned to surgery) underwent surgical TVR with concomitant CABG
250	during the follow-up period.

252 Survival

Each patient in the study had a follow-up time of at least six months or until death. Inhospital and 18-month mortality were highest amongst the patients assigned to TTVI (19.3%, 28.1%) and medical therapy with late presentation (18.5%, 28.9%; Table 4).

In Figure 4, we present the survival curves for the whole cohort compared to survival 256 257 curves of each treatment group, with medical therapy divided into early and advanced groups. 258 The mean overall survival time in the total cohort was 14.5 months \pm a standard error of 0.4 259 months (95% confidence interval [CI] = 13.74 - 15.31 months). Survival time was shortest in 260 those assigned to TTVI (13.3 ± 1.2 months, 95% CI = 11.0 - 15.6) and medical therapy with advanced stage (14.0 ± 0.5 months, 95% CI = 13.1 - 14.9). Those assigned to medical therapy 261 with early presentation had the longest overall survival (18.1 ± 1.0 months, 95% CI = 16.1 - 10%262 20.0), followed by those assigned to surgery $(15.1 \pm 1.0 \text{ months}, 95\% \text{ CI} = 13.2 - 17.0)$. 263

264

265 **TR Management in Actual Practice**

Of the 470 patients retrospectively assigned to medical therapy by the ESC guidelines, 97.7% (459/470) received medical therapy, nine underwent TV surgery, and two underwent TTVI. Our center currently performs heterotopic caval valve implantation (TricValve®) on a compassionate-use basis. Of the 54 patients assigned to TV surgery, 79.6% (43/54) received

270	medical therapy, and 20.4% (11/54) underwent TV surgery, one of which was concomitant TVR
271	with CABG. One of the patients assigned to TTVI underwent TricValve® implantation, two
272	underwent TV surgery, and the remaining 54 received medical therapy. In total, 556 of the
273	patients received medical therapy, 22 underwent TV surgery, and three received TTVI during the
274	study's follow-up period.

276 **DISCUSSION**

In this retrospective study of consecutive patients with more than moderate TR presenting to 277 278 a tertiary care center, we showed that a minority (9.8%) could qualify for TTVI, and 76.2% had advanced left or right ventricular dysfunction or severe pulmonary hypertension precluding any 279 surgical or transcatheter intervention. The in-hospital and 18-month mortality rates were grimly 280 281 high in the advanced stage medical therapy and TTVI cohorts at 18.5%, 28.9% and 19.3%, 28.1%, respectively. Although we are unable to comment on which specific TTVI device 282 patients are candidates for, our study sheds light on the clinical and echocardiographic 283 characteristics of this patient population and their outcomes at a tertiary care center. 284 There are currently four categories of TTVI, which are at various developmental stages: 285 coaptation devices (TriClip[®], Pascal[®], Dragonfly[®], FORMA[®]), annuloplasty devices 286 (cardioband[®], K-Clip[®], Trialign[®], TriCinch[®]) orthotopic replacement (Evoque[®], Lux[®], Intrepid[®]) 287 and heterotopic replacement (TricValve®, Trillium®). The first three devices aim to reduce TR 288 289 severity, and the last one reduces venous congestion caused by it. There are no commercially available TR-reducing transcatheter devices in the United States, and the TricValve[®] is only 290 available for compassionate use. Some coaptation (TriClip[®] and Pascal[®]) and annuloplasty 291 292 devices (cardioband[®]) are commercially available in Europe, and the TriClip is expected to get

293 approval from the Food and Drug Administration in the United States following the Trial to Evaluate Treatment with Abbott Transcatheter Clip Repair System in Patients with Moderate or 294 Greater Tricuspid Regurgitation (TRILUMINATE) meeting its primary endpoint.¹⁸⁻¹⁹ 295 Although several non-randomized controlled trials (RCT's)²⁰⁻²⁷ using various types of TTVI 296 devices showed symptomatic relief, the ideal timing of intervention to impact survival remains to 297 be defined.²⁸⁻²⁹ The TRILUMINATE study on tricuspid edge-to-edge repair is the only RCT 298 testing a TTVI device.¹⁹ It showed that TriClip met its primary composite endpoint of all-cause 299 mortality, tricuspid valve surgery, heart failure hospitalizations, and quality-of-life improvement 300 301 using the Kansas City Cardiomyopathy Questionnaire (KCCQ) score at 12 months, but that was mainly driven by improvements in the KCCQ score. It is unclear at this stage if mortality would 302 be reduced by Triclip after the two-year follow-up planned for this trial is completed. 303 304 While heterotopic TV replacement is a catheter-based device, it is generally a non-corrective procedure, and for the purposes of our study, we did not consider it TTVI. Except for the three 305 patients who underwent TricValve implantation, none underwent TTVI because we did not have 306 access to these therapies during the study period. Therefore, the 28.1% mortality rate of the 307 patients allocated to the TTVI group reflects the untreated mortality rate of this cohort. This rate 308 is almost threefold higher than the 10.6% mortality rate seen in the control arm of the 309 TRILUMINATE trial, which is not surprising given the higher prevalence of comorbidities and 310 advanced-stage disease in our TTVI group (liver cirrhosis 36.6%, CKD 65.9%, ESRD 19.3%) 311 312 compared to the control group enrolled in TRILUMINATE (liver disease 9.1%, CKD 35.4%, ESRD 0%).¹⁹ 313

The characteristics of the patients who are candidates for TTVI in our study mirror those of the TriValve registry patients.³⁰ This registry is an ongoing, prospective database of all patients

undergoing TTVI outside of RCT's. In 2017, they reported on 107 patients with clinically
significant TR treated with various TTVI devices, mainly the MitraClip device. The mean age
was 76 years, atrial fibrillation 79%, female 60%, ascites 27%, NYHA class III or IV 95%, prior
left-sided valve surgery 26%, mean LVEF 51%, and mean TAPSE 16 mm. These demographics
and clinical variables were very similar to our TTVI patient cohort; mean age of 75 years, atrial
arrhythmia 79%, female 56%, ascites 35%, NYHA class III or IV 82%, prior valve surgery 26%,
mean LVEF 54%, and mean TAPSE 20 mm.

The TTVI treatment group in our study was derived from a pool of patients who presented to 323 324 our tertiary care center with an already high burden of comorbidities and end-organ disease (liver cirrhosis 17.7%, CKD 64.0%, ESRD 19.8%) and a 26.7% mortality rate. There is a direct 325 association between TR severity and mortality^{8, 31-33}, but comorbidities, which are indicators of 326 late presentation and end-organ failure, predict mortality independent of TR severity.¹⁷ 327 Breitninger et al. showed that age, male gender, renal dysfunction, presence of CHF, liver 328 disease, lung disease, and TR severity were independently associated with mortality.²² Topilsky 329 et al. showed that left sided valvular disease and LV systolic dysfunction were associated with 330 the poorest survival in patients with functional TR, followed by pulmonary hypertension and 331 primary TR.¹⁷ 332

As discussed above, our study's patient population had a high burden of comorbidities and signs of end-stage disease than the TRILUMINATE population. Therefore, TTVI performed at the advanced stage noted in our inpatient cohort may not impact survival although it could improve quality of life. A suggestion that this might be the case comes from the Mayo Clinic study by Breitinger et al. done in 13,608 with moderate to severe TR and a median follow-up of 6.5 years.³³ In patients with significant comorbidities, the severity of TR was not associated with

339 differences in survival. In contrast, in those with fewer comorbidities, increasing TR severity was associated with worse survival. Another study showed similar results. Neuhold et al. studied 576 340 patients with heart failure and noted that TR severity was predictive of poor outcomes in those 341 with mildly to moderately impaired LV function but not in those with a severely depressed EF.³⁴ 342 Nonetheless, it is reassuring that the TriValve registry reported a low all-cause 30-day mortality 343 rate of 3.7% in 106 patients who underwent TTVI, despite a high prevalence of comorbidities.³⁰ 344 It is unclear, however, if there are unreported factors that led to a selection bias in the TriValve 345 registry, resulting in a more favorable 30-day mortality rate. 346

Tricuspid regurgitation is a complex disease with etiology having an impact on management 347 348 and outcomes. Most TR is functional, thus the rate of progression and success of treatment depends on non-tricuspid valve drivers, such as aortic and mitral valvular disease, ventricular 349 function, and arrhythmia control.³⁵ Clinical trials of TTVI devices aiming to reduce TR will 350 need to account for these diseases. Adding to the complexity is the fragile nature of the right 351 ventricle that is not designed to withstand chronic pressure and volume overload. Seventy six 352 percent of the patients in our study had disease too advanced for any intervention with a 353 mortality rate just under 30% by 18 months. This rate stresses the importance of early detection 354 that should initiate a comprehensive management plan for all factors contributing to TR, and 355 early referral for intervention.³⁶ 356

Therefore, future clinical trials using TTVI devices should not only focus on patients with advanced stages but also on those at earlier or even asymptomatic stages of TR where early intervention may confer a survival benefit in addition to symptomatic benefit.³⁷ The Mayo Clinic reported that patients with a low TRIO (Tricuspid Regurgitation Impact on Outcomes) score with

few comorbidities might benefit the most from interventions to correct TR, based on 10-year allcause mortality.³³ Provided that evidence of improved survival may be realized with longer
follow-up, we expect that TTVI guidelines would eventually evolve to include lower-risk
patients, analogous to the evolution of the guidelines for the transcatheter aortic valve
implantation (TAVI) procedure.

Limitations of this retrospective, single-center analysis merit consideration. NYHA 366 367 functional class was not defined for over half of our cohort, and thus physical exam history of lower extremity edema or ascites was used to indicate signs of RHF instead. Due to differences 368 in patients' transthoracic echocardiogram imaging, some echocardiographic parameters, such as 369 370 the S' or TAPSE were not measurable for all patients. Furthermore, the ESC 2021 guidelines do not specifically define parameters for determining appropriateness for surgery, so we used our 371 own criteria, which may have underestimated the number of patients who were too high risk for 372 373 surgery.

The present study findings show that most patients presenting to a tertiary care center 374 with more than moderate TR are too advanced for any intervention and have high in-hospital and 375 late mortality rates. We illustrated that a minority of these patients would clinically qualify for 376 TTVI. There is a need to improve care for patients with TR through earlier detection that should 377 initiate a comprehensive management plan for all factors contributing to TR, and early referral 378 for intervention. Future clinical trials with longer follow up will be needed to assess TTVI 379 devices in patients at earlier or even asymptomatic stages of TR when there may be a greater 380 381 likelihood of improving survival.

383 ACKNOWLEDGEMENTS

- 384 The authors acknowledge the invaluable assistance of the structural cardiology team at the
- Tampa General Hospital Heart and Vascular Institute in the conduct of this study.
- 386 Conceptualization and methodology: A.O.D.C., C.B.S, D.R.C., and F.A.M. Investigation:
- A.O.D.C., C.B.S, S.N.M., and J.A.M. Formal analysis and interpretation: A.O.D.C., C.B.S,
- 388 D.R.C., and F.A.M. Writing: A.O.D.C., C.B.S, and F.A.M. Writing–review and editing and
- supervision: A.O.D.C., C.B.S, S.N.M., J.A.M., D.R.C., and F.A.M.
- 390

391 SOURCES OF FUNDING

- 392 This study did not include any sources of funding.
- 393

394 **DISCLOSURES**

395 None.

397 REFERENCES

- 1. Nath J, Foster E, Heidenreich PA. Impact of tricuspid regurgitation on long-term survival. J
- 399 *Am Coll Cardiol.* 2004 Feb 4;43(3):405-9. doi: 10.1016/j.jacc.2003.09.036.
- 400
- 401 2. Agricola E, Stella S, Gullace M, Ingallina G, D'Amato R, Slavich M, Oppizzi M, Ancona MB,

402 Margonato A. Impact of functional tricuspid regurgitation on heart failure and death in patients

403 with functional mitral regurgitation and left ventricular dysfunction. *Eur J Heart Fail*. 2012

404 Aug;14(8):902-8. doi: 10.1093/eurjhf/hfs063.

405

406 3. Dahou A, Magne J, Clavel MA, Capoulade R, Bartko PE, Bergler-Klein J, Sénéchal M,

407 Mundigler G, Burwash I, Ribeiro HB, et al. Tricuspid Regurgitation Is Associated With

408 Increased Risk of Mortality in Patients With Low-Flow Low-Gradient Aortic Stenosis and

409 Reduced Ejection Fraction: Results of the Multicenter TOPAS Study (True or Pseudo-Severe

410 Aortic Stenosis). *JACC Cardiovasc Interv*. 2015 Apr 20;8(4):588-96. doi:

411 10.1016/j.jcin.2014.08.019.

412

4. Fujisawa T, Kimura T, Ikemura N, Miyama H, Katsumata Y, Ueda I, Tanimoto K, Kanki H,
Fukuda K, Kohsaka S, et al. Effect of Tricuspid Regurgitation on the Reported Quality of Life
and Subsequent Outcomes in Patients With Atrial Fibrillation. *J Am Heart Assoc*. 2022 Apr
19;11(8):e022713. doi: 10.1161/JAHA.121.022713.

417

419 Echocardiographic Determinants of One-Year All-Cause Mortality in Patients With Chronic

^{5.} Hu K, Liu D, Störk S, Herrmann S, Oder D, Ertl G, Voelker W, Weidemann F, Nordbeck P.

420	Heart Failure Complicated by Significant Functional Tricuspid Regurgitation. J Card Fail. 2017
421	Jun;23(6):434-443. doi: 10.1016/j.cardfail.2016.11.005.

423	6. Mutlak D, L	essick J, Khalil S	, Yalonetsky	S, Agmon Y	, Aronson D.	Tricuspid re	egurgitation in
-----	----------------	--------------------	--------------	------------	--------------	--------------	-----------------

424 acute heart failure: is there any incremental risk? *Eur Heart J Cardiovasc Imaging*. 2018 Sep

425 1;19(9):993-1001. doi: 10.1093/ehjci/jex343. PMID: 29346535.

426

427 7. Santas E, Chorro FJ, Miñana G, Méndez J, Muñoz J, Escribano D, García-Blas S, Valero E,

428 Bodí V, Núñez E, et al. Tricuspid Regurgitation and Mortality Risk Across Left Ventricular

429 Systolic Function in Acute Heart Failure. *Circ J.* 2015;79(7):1526-33. doi: 10.1253/circj.CJ-15430 0129.

431

432 8. Wang N, Fulcher J, Abeysuriya N, McGrady M, Wilcox I, Celermajer D, Lal S. Tricuspid

433 regurgitation is associated with increased mortality independent of pulmonary pressures and

right heart failure: a systematic review and meta-analysis. Eur Heart J. 2019 Feb 1;40(5):476-

435 484. doi: 10.1093/eurheartj/ehy641.

436

438 Nishimura RA. National Trends and Outcomes in Isolated Tricuspid Valve Surgery. J Am Coll

439 *Cardiol.* 2017 Dec 19;70(24):2953-2960. doi: 10.1016/j.jacc.2017.10.039.

^{437 9.} Zack CJ, Fender EA, Chandrashekar P, Reddy YNV, Bennett CE, Stulak JM, Miller VM,

441	10. Weiss T, Villadsen PR, Jensen JK, Lehnert P, Nielsen PH, Modrau IS. Outcomes of isolated
442	tricuspid valve surgery in contemporary practice. Eur J Cardiothorac Surg. 2022 Jul
443	11;62(2):ezac077. doi: 10.1093/ejcts/ezac077.
444	
445	11. Axtell AL, Bhambhani V, Moonsamy P, Healy EW, Picard MH, Sundt TM 3rd, Wasfy JH.
446	Surgery Does Not Improve Survival in Patients With Isolated Severe Tricuspid Regurgitation. J
447	Am Coll Cardiol. 2019 Aug 13;74(6):715-725. doi: 10.1016/j.jacc.2019.04.028.

- 12. Brescia AA, Ward ST, Watt TMF, Rosenbloom LM, Baker M, Khan S, Ziese E, Romano
- 450 MA, Bolling SF; Michigan Mitral Research Group (MMRG). Outcomes of Guideline-Directed
- 451 Concomitant Annuloplasty for Functional Tricuspid Regurgitation. Ann Thorac Surg. 2020

452 Apr;109(4):1227-1232. doi: 10.1016/j.athoracsur.2019.07.035.

453

13. Blusztein DI, Hahn RT. New therapeutic approach for tricuspid regurgitation: Transcatheter
tricuspid valve replacement or repair. *Front Cardiovasc Med.* 2023 Feb 23;10:1080101. doi:
10.3389/fcvm.2023.1080101.

457

14. Stuge O, Liddicoat J. Emerging opportunities for cardiac surgeons within structural heart
disease. *J Thorac Cardiovasc Surg.* 2006 Dec;132(6):1258-61. doi: 10.1016/j.jtcvs.2006.08.049.

- 15. Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, Capodanno D,
- 462 Conradi L, De Bonis M, De Paulis R, et al. 2021 ESC/EACTS Guidelines for the management of
- 463 valvular heart disease. *Eur Heart J.* 2022 Feb 12;43(7):561-632. doi: 10.1093/eurheartj/ehab395.

465	16. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA,
466	Foster E, Goldstein SA, Kuznetsova T, et al. Recommendations for cardiac chamber
467	quantification by echocardiography in adults: an update from the American Society of
468	Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc
469	Echocardiogr. 2015 Jan;28(1):1-39.e14. doi: 10.1016/j.echo.2014.10.003.
470	
471	17. Topilsky Y, Maltais S, Medina Inojosa J, Oguz D, Michelena H, Maalouf J, Mahoney DW,
472	Enriquez-Sarano M. Burden of Tricuspid Regurgitation in Patients Diagnosed in the Community
473	Setting. JACC Cardiovasc Imaging. 2019 Mar;12(3):433-442. doi: 10.1016/j.jcmg.2018.06.014.
474	
475	18. Hahn RT, Nabauer M, Zuber M, Nazif TM, Hausleiter J, Taramasso M, Pozzoli A, George I,
476	Kodali S, Bapat V, et al. Intraprocedural Imaging of Transcatheter Tricuspid Valve
477	Interventions. JACC Cardiovasc Imaging. 2019 Mar;12(3):532-553. doi:
478	10.1016/j.jcmg.2018.07.034.
479	
480	19. Sorajja P, Whisenant B, Hamid N, Naik H, Makkar R, Tadros P, Price MJ, Singh G, Fam N,
481	Kar S, et al. Transcatheter Repair for Patients with Tricuspid Regurgitation. N Engl J Med. 2023
482	May 18;388(20):1833-1842. doi: 10.1056/NEJMoa2300525.
483	
484	20. Sorajja P, Cavalcante JL, Gossl M, Bae R. Transcatheter repair of tricuspid regurgitation
485	with MitraClip. Prog Cardiovasc Dis. 2019 Nov-Dec;62(6):488-492. doi:
486	10.1016/j.pcad.2019.10.001.

488	21. Fam NP, Braun D, von Bardeleben RS, Nabauer M, Ruf T, Connelly KA, Ho E, Thiele H,
489	Lurz P, Weber M, et al. Compassionate Use of the PASCAL Transcatheter Valve Repair System
490	for Severe Tricuspid Regurgitation: A Multicenter, Observational, First-in-Human Experience.
491	JACC Cardiovasc Interv. 2019 Dec 23;12(24):2488-2495. doi: 10.1016/j.jcin.2019.09.046.
492	
493	22. Lurz P, Besler C, Noack T, Forner AF, Bevilacqua C, Seeburger J, Rommel KP, Blazek S,
494	Hartung P, Zimmer M, et al. Transcatheter treatment of tricuspid regurgitation using edge-to-
495	edge repair: procedural results, clinical implications and predictors of success. EuroIntervention.
496	2018 Jun 8;14(3):e290-e297. doi: 10.4244/EIJ-D-17-01091.
497	
498	23. Mehr M, Taramasso M, Besler C, Ruf T, Connelly KA, Weber M, Yzeiraj E, Schiavi D,
499	Mangieri A, Vaskelyte L, et al. 1-Year Outcomes After Edge-to-Edge Valve Repair for
500	Symptomatic Tricuspid Regurgitation: Results From the TriValve Registry. JACC Cardiovasc
501	Interv. 2019 Aug 12;12(15):1451-1461. doi: 10.1016/j.jcin.2019.04.019. PMID: 31395215.
502	
503	24. Braun D, Orban M, Orban M, Hagl C, Massberg S, Nabauer M, Hausleiter J. Transcatheter
504	Edge-to-Edge Repair for Severe Tricuspid Regurgitation Using the Triple-Orifice Technique
505	Versus the Bicuspidalization Technique. JACC Cardiovasc Interv. 2018 Sep 10;11(17):1790-
506	1792. doi: 10.1016/j.jcin.2018.05.049.
507	
508	25. Braun D, Löw K, Orban M, Mehr M, Gmeiner J, Massberg S, Nabauer M, Hausleiter J.
509	Mitraclip XTR VS. pascal transcatheter valve repair system for edge-to-edge repair of severe

tricuspid regurgitation. J Am College Cardiol. (2020) 75:1135. doi: 10.1016/S07351097(20)31762-9.

512

- 513 26. Perlman G, Praz F, Puri R, Ofek H, Ye J, Philippon F, Carrel T, Pibarot P, Attinger A, Htun
- 514 NM. Transcatheter Tricuspid Valve Repair With a New Transcatheter Coaptation System for the
- 515 Treatment of Severe Tricuspid Regurgitation: 1-Year Clinical and Echocardiographic Results.
- 516 JACC Cardiovasc Interv. 2017 Oct 9;10(19):1994-2003. doi: 10.1016/j.jcin.2017.06.036.

517

- 518 27. Asmarats L, Perlman G, Praz F, Hensey M, Chrissoheris MP, Philippon F, Ofek H, Ye J, Puri
- 519 R, Pibarot P, et al. Long-Term Outcomes of the FORMA Transcatheter Tricuspid Valve Repair

520 System for the Treatment of Severe Tricuspid Regurgitation: Insights From the First-in-Human

521 Experience. JACC Cardiovasc Interv. 2019 Aug 12;12(15):1438-1447. doi:

522 10.1016/j.jcin.2019.04.038. PMID: 31395213.

- 523
- 524 28. Bocchino PP, Angelini F, Vairo A, Andreis A, Fortuni F, Franchin L, Frea S, Raineri C,
- 525 Pidello S, Conrotto F, et al. Clinical Outcomes Following Isolated Transcatheter Tricuspid Valve

526 Repair: A Meta-Analysis and Meta-Regression Study. JACC Cardiovasc Interv. 2021 Oct

527 25;14(20):2285-2295. doi: 10.1016/j.jcin.2021.08.050.

- 528
- 529 29. Sannino A, Ilardi F, Hahn RT, Lancellotti P, Lurz P, Smith RL, Esposito G, Grayburn PA.
- 530 Clinical and Echocardiographic Outcomes of Transcatheter Tricuspid Valve Interventions: A
- 531 Systematic Review and Meta-Analysis. *Front Cardiovasc Med.* 2022 Jul 11;9:919395. doi:
- 532 10.3389/fcvm.2022.919395. PMID: 35898276; PMCID: PMC9309386.

534	30. Taramasso M, Hahn RT, Alessandrini H, Latib A, Attinger-Toller A, Braun D, Brochet E,
535	Connelly KA, Denti P, Deuschl F, et al. The International Multicenter TriValve Registry: Which
536	Patients Are Undergoing Transcatheter Tricuspid Repair? JACC Cardiovasc Interv. 2017 Oct
537	9;10(19):1982-1990. doi: 10.1016/j.jcin.2017.08.011. PMID: 28982563.
538	
539	31. Chorin E, Rozenbaum Z, Topilsky Y, Konigstein M, Ziv-Baran T, Richert E, Keren G, Banai
540	S. Tricuspid regurgitation and long-term clinical outcomes. Eur Heart J Cardiovasc Imaging.
541	2020 Feb 1;21(2):157-165. doi: 10.1093/ehjci/jez216.
542	
543	32. Bartko PE, Arfsten H, Frey MK, Heitzinger G, Pavo N, Cho A, Neuhold S, Tan TC, Strunk
544	G, Hengstenberg C, et al. Natural History of Functional Tricuspid Regurgitation: Implications of
545	Quantitative Doppler Assessment. JACC Cardiovasc Imaging. 2019 Mar;12(3):389-397. doi:
546	10.1016/j.jcmg.2018.11.021.
547	
548	33. Lara-Breitinger KM, Scott CG, Nkomo VT, Pellikka PA, Kane GC, Chaliki HP, Shapiro BP,
549	Eleid MF, Alkhouli M, Greason KL, et al. Tricuspid Regurgitation Impact on Outcomes (TRIO):
550	A Simple Clinical Risk Score. Mayo Clin Proc. 2022 Aug;97(8):1449-1461. doi:
551	10.1016/j.mayocp.2022.05.015.
552	
553	34. Neuhold S, Huelsmann M, Pernicka E, Graf A, Bonderman D, Adlbrecht C, Binder T,

Maurer G, Pacher R, Mascherbauer J. Impact of tricuspid regurgitation on survival in patients

- with chronic heart failure: unexpected findings of a long-term observational study. *Eur Heart J*.
 2013 Mar;34(11):844-52. doi: 10.1093/eurheartj/ehs465.
- 557
- 558 35. Hahn RT. Tricuspid Regurgitation. *N Engl J Med.* 2023 May 18;388(20):1876-1891. doi:
 559 10.1056/NEJMra2216709.
- 560
- 36. Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP 3rd, Gentile F, Jneid H,
- 562 Krieger EV, Mack M, McLeod C, et al. 2020 ACC/AHA Guideline for the Management of
- 563 Patients With Valvular Heart Disease: Executive Summary: A Report of the American College
- of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

565 *Circulation*. 2021 Feb 2;143(5):e35-e71. doi: 10.1161/CIR.00000000000932.

566

- 37. Grubb, KJ and Malaisrie, SC. Illuminating the TRILUMINATE Trial. American College of
 Cardiology Expert Review, May 23, 2023. Accessed August 26 2023.
- https://www.acc.org/latest-in-cardiology/articles/2023/05/23/10/26/illuminating-the-triluminatetrial.

571

- 572 38. Bocchino PP, Angelini F, Alushi B, Conrotto F, Cioffi GM, Tersalvi G, Senatore G,
- 573 Pedrazzini G, De Ferrari GM, Biasco L. Transcatheter Aortic Valve Replacement in Young
- 574 Low-Risk Patients With Severe Aortic Stenosis: A Review. Front Cardiovasc Med. 2020 Dec
- 575 14;7:608158. doi: 10.3389/fcvm.2020.608158.

TABLES

Variables	N = 581
Male	277 (47.7)
Female	304 (52.3)
Age, years	65.67 ± 17.35
BMI, kg/m^2	28.0 ± 8.36
Race	
White	325 (55.9)
Black	174 (29.9)
Arab or Middle Eastern	2 (0.3)
Haitian	4 (0.7)
Puerto Rican	14 (2.4)
Cuban	6 (1.0)
Asian	7 (1.2)
Other	49 (8.4)
Ethnicity	
Hispanic or Latino	66 (11.4)
Other	515 (88.6)
Symptoms of right heart failure	
LE edema	394 (67.8)
Ascites	199 (34.3)
NYHA Class	
0	4/298 (1.3)
I	17/298 (5.7)
II	43/298 (14.4)
III	175/298 (58.7)
IV	59/298 (19.8)

Table 1. Baseline clinical characteristics of the total cohort.

Past medical history

Hypertension	466 (80.2)
Valve surgery	124 (21.3)
CABG	12 (2.1)
Open heart surgery	172 (29.6)
A-fib or A-flutter	354 (60.9)
Pacemaker or ICD	197 (33.9)
COPD	179 (30.8)
Cirrhosis	103 (17.7)
Diabetes Mellitus	279 (48.0)
CKD	372 (64.0)
ESRD	115 (19.8)
eGFR [*]	
eGFR ≥60 mL/min	187/391 (47.8)
eGFR <60 mL/min	203/391 (51.9)
eGFR if <60, mL/min	31.0 [15.0, 46.0]

- 579 Values are n (%) mean \pm SD, n/N (%), or median [first quartile, third quartile]. *eGFR was not
- so available for patients of age >70 years.
- 581 A-fib or A-flutter = atrial fibrillation or atrial flutter; BMI = body mass index; CABG = coronary
- artery bypass graft; CKD = chronic kidney disease; COPD = chronic obstructive pulmonary
- 583 disease; eGFR = estimated glomerular filtration rate; ERSD = end-stage renal disease; ICD =
- implantable cardiac defibrillator; LE edema = lower extremity edema.

585

586

Variables	N = 581
Peak TR velocity, m/s (N = 573)	3.40 [2.93, 3.89]
RA Pressure, mmHg ($N = 519$)	15.0 [8.0, 15.0]
Tricuspid valve vegetation	19 (3.3)
Prior TVR	9 (1.6)
Prior TV annuloplasty	7 (1.2)
Secondary TR	539 (92.8)
Primary TR	42 (7.2)
Primary TR type: Endocarditis	33/42 (78.6)
Primary TR type: Carcinoid	2/42 (4.8)
Primary TR type: Lead impingement	6/42 (14.3)
Primary TR type: Congenital	1/42 (2.4)
Pacemaker lead present	121 (20.8)
Right Ventricle	
TAPSE, mm (N = 461)	15.0 [12.0, 20.0]
S', cm/s (N = 276)	9.60 [7.45, 11.70]
RVSP, mmHg (N = 517)	58.0 [44.75, 72.0]
Base size, cm (N = 526)	4.40 [3.80, 5.10]
Mid-cavitary size, cm ($N = 489$)	3.80 [3.30, 4.40]
Longitudinal size, cm ($N = 525$)	7.20 [6.30, 8.20]
HV flow reversal	149/279 (53.4)
Pulmonary hypertension	
None, ≤34 mmHg	45/537 (8.4)
Mild, 35 – 44 mmHg	86/537 (16.0)
Moderate, 45 – 54 mmHg	100/537 (18.6)
Severe, ≥55 mmHg	306/537 (57.0)
TAPSE/PASP, mm/mmHg (N = 432)	0.27 [0.19, 0.38]

Table 2. Echocardiographic parameters of the total cohort.

Left heart valve dysfunction

>Moderate MR	51 (8.8)			
>Moderate MS	5 (0.9)			
>Moderate AR	9 (1.5)			
>Moderate AS	6 (1.0)			
Any of the above	64 (11.0)			
None of the above	517 (89.0)			
Qualified for left-sided valve surgery	25 (4.3)			
Left ventricular dysfunction by LVEF				
None, LVEF 50% – 75%	337 (58.0)			
Mild, LVEF 40% – 49%	53 (9.1)			
Moderate, LVEF 30% – 39%	40 (6.9)			
Severe, LVEF <30%	151 (26.0)			

589 Values are median [first quartile, third quartile], n (%), or n/N (%).

590 AR = aortic regurgitation; AS = aortic stenosis; LVEF = left ventricular ejection fraction; MR =

591 mitral regurgitation; MS = mitral stenosis; RA Pressure = right atrial pressure; RVSP = right

592 ventricular systolic pressure; TAPSE = tricuspid annular plane systolic excursion; TAPSE/PASP

593 = Tricuspid annular plane systolic excursion/pulmonary artery systolic pressure; TR = tricuspid

regurgitation; TV = tricuspid valve; TVR = tricuspid valve repair or replacement.

		Medical th			
Parameters	Total cohort	Advanced stage	Early stage	Surgery	TTVI
i ai ainetei s	N = 581	N = 443	N = 27	N = 54	N = 57
Primary TR	42 (7.2)	12 (2.7)	9 (33.3)	16 (29.6)	5 (8.8)
Functional TR	539 (92.8)	431 (97.3)	18 (66.7)	38 (70.4)	52 (91.2)
Left valvular disease	60 (10.3)	33 (7.4)	2 (7.4)	23 (41.8)	2 (3.5)
LV systolic dysfunction	157 (27.0)	150 (33.9)	1 (3.7)	1 (1.8)	5 (8.8)
Severe pulmonary HTN	197 (33.9)	197 (44.5)	0	0	0
Isolated TR	125 (21.5)	51 (11.5)	15 (55.6)	14 (25.5)	45 (61.6)

Table 3. TR Etiology in the total cohort and by assigned treatment group.

597 Values are n (%). Left valvular disease was defined as greater than moderate mitral or aortic

valve regurgitation or stenosis. LV systolic dysfunction was defined as LV ejection fraction

599 <40% and absence of moderate-severe left valvular disease. Severe pulmonary hypertension was

defined as pulmonary arterial pressure > 55 mmHg or TR jet velocity >3.6m/s with systolic

septal flattening and absence of both moderate-severe left valvular disease and LV systolic

602 dysfunction. Isolated TR was defined by the absence of severe pulmonary hypertension,

603 moderate-severe left valvular disease, and LV systolic dysfunction.

HTN = hypertension; LV = left ventricular; TR = tricuspid regurgitation.

605

Medical therapy						
Mortality	Total cohort	Advanced stage	Early stage	Surgery	TTVI	
-	N = 581	N = 443	N = 27	N = 54	N = 57	
In-hospital	98 (16.9)	82 (18.5)	1 (3.7)	4 (7.4)	11 (19.3)	
Late	57 (9.8)	46 (10.4)	1 (3.7)	5 (9.3)	5 (8.8)	
Total	155 (26.7)	128 (28.9)	2 (7.4)	9 (16.7)	16 (28.1)	

p.
ľ

608 Values are n (%).

TTVI = transcatheter tricuspid valve intervention.

610








Figure 1. Management of tricuspid regurgitation based on the 2021 ESC guidelines 616

The 2021 European Society of Cardiology (ESC) guidelines for the management of valvular 617


618 disease include an algorithm for determining the management of tricuspid regurgitation (TR):

medical therapy, transcatheter tricuspid valve intervention (TTVI) or surgery (Sx). 619

RV dilatation = right ventricular dilatation; Severe RV/LV dysfunction/PAH= severe right 620


621 ventricular or left ventricular dysfunction or severe pulmonary arterial hypertension.

622






- 625 Figure 2. The modified ESC algorithm
- We modified the 2021 ESC algorithm for determining the management of tricuspid regurgitation
- 627 (orange dashed lines and orange borders). Abbreviations as in Figure 1.




630

Figure 3. Applying the modified ESC algorithm

- 632 We applied the modified European Society of Cardiology (ESC) algorithm to our cohort of 581
- patients with more than moderate TR and determined the numbers of patients who were
- 634 candidates for medical therapy, TTVI, or Sx. Abbreviations as in Figure 1.







Kaplan-Meier curves of overall survival in the total cohort and by assigned treatment group, with 639 640 medical therapy divided into early and late stage (see Methods for definition of early vs. late). The mean overall survival time in the total cohort was 14.5 months \pm a standard error of 0.4 641 months (95% confidence interval [CI] = 13.74 - 15.31 months). The mean overall survival time 642 was shortest in the groups assigned to TTVI (13.3 ± 1.2 months, 95% CI = 11.0 - 15.6) and 643 medical therapy with advanced stage (14.0 ± 0.5 months, 95% CI = 13.1 - 14.9). The 27 patients 644 assigned to medical therapy with early presentation had the longest overall survival (18.1 \pm 1.0 645 months, 95% CI = 16.1 - 20.0), followed by those assigned to surgery (15.1 ± 1.0 months, 95% 646 CI = 13.2 - 17.0). 647

- 648
- 649